We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+35.03%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$893M
AUM Growth
-$316M
Cap. Flow
-$200M
Cap. Flow %
-22.43%
Top 10 Hldgs %
73.65%
Holding
46
New
3
Increased
4
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$22.1M
2
CDTX
Cidara Therapeutics
CDTX
+$10.9M
3
DRUG
Bright Minds Biosciences
DRUG
+$8.85M
4
DCTH icon
Delcath Systems
DCTH
+$7.51M
5
TRVI icon
Trevi Therapeutics
TRVI
+$6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$104M
2
SVA
Sinovac Biotech, Ltd
SVA
+$76.3M
3
VRNA
Verona Pharma
VRNA
+$47.5M
4
VRDN icon
Viridian Therapeutics
VRDN
+$15.1M
5
ALXO icon
ALX Oncology
ALXO
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$283M 31.68%
6,291,851
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$106M 11.88%
2,283,975
-1,265,783
-36% -$47.5M
GERN icon
3
Geron
GERN
$930M
$96.4M 10.8%
27,225,292
– –
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$38.2M 4.28%
6,895,746
– –
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$28.2M 3.16%
2,684,109
– –
DYN icon
6
Dyne Therapeutics
DYN
$4.28B
$26.3M 2.94%
1,114,960
– –
ACRS icon
7
Aclaris Therapeutics
ACRS
$744M
$22M 2.47%
+8,888,888
New +$22.1M
DCTH icon
8
Delcath Systems
DCTH
$399M
$20.6M 2.3%
1,708,579
+711,574
+71% +$7.51M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.15B
$18.8M 2.11%
982,576
-695,631
-41% -$15.1M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$18M 2.02%
+670,600
New +$10.9M
ERAS icon
11
Erasca
ERAS
$6.3B
$17M 1.9%
6,756,756
– –
TRVI icon
12
Trevi Therapeutics
TRVI
$2.62B
$14.4M 1.61%
3,487,903
+1,875,000
+116% +$6M
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$13.9M 1.56%
1,552,685
– –
RZLT icon
14
Rezolute
RZLT
$474M
$13.7M 1.54%
2,797,704
– –
SERA icon
15
Sera Prognostics
SERA
$79.5M
$13.4M 1.51%
1,650,440
– –
TRML
16
DELISTED
Tourmaline Bio
TRML
$12M 1.34%
591,882
– –
CRVS icon
17
Corvus Pharmaceuticals
CRVS
$1.12B
$12M 1.34%
2,234,566
+737,298
+49% +$5.5M
TIL icon
18
Instil Bio
TIL
$49.4M
$11.2M 1.25%
585,485
-38,854
-6% -$1.18M
ORIC icon
19
Oric Pharmaceuticals
ORIC
$1.23B
$10.3M 1.16%
1,277,818
– –
ABEO icon
20
Abeona Therapeutics
ABEO
$343M
$10.3M 1.15%
1,842,751
– –
ZBIO
21
Zenas BioPharma
ZBIO
$2.04B
$9.69M 1.09%
1,183,260
– –
DRUG
22
Bright Minds Biosciences
DRUG
$706M
$9.06M 1.02%
+251,572
New +$8.85M
OLMA icon
23
Olema Pharmaceuticals
OLMA
$1.01B
$8.78M 0.98%
1,505,862
– –
COGT icon
24
Cogent Biosciences
COGT
$6.95B
$8.76M 0.98%
1,122,471
– –
CELC icon
25
Celcuity
CELC
$4.02B
$7.99M 0.9%
610,500
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Vivo Capital held 46 positions worth $893M, down 26% from $1.21B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Vivo Capital withdrew a net $200M in Q4 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Harmony Biosciences, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Aclaris Therapeutics worth $22M.

  • Vivo Capital's largest Q4 2024 buy was Aclaris Therapeutics: 8,888,888 shares worth $22M.
  • Vivo Capital added most to Delcath Systems in Q4 2024, an estimated $7.51M increase.
  • Vivo Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $47.5M.
  • Vivo Capital fully exited Harmony Biosciences in Q4 2024, selling an estimated $104M.
  • Vivo Capital's ten largest holdings make up 74% of its $893M portfolio in Q4 2024.
  • Vivo Capital opened 3 new positions and closed 6 in Q4 2024.
  • Vivo Capital's portfolio value fell 26% quarter-over-quarter to $893M.

Based on Vivo Capital's 13F filing for Q4 2024, filed 13 Feb 2025.